Cerulean (NASDAQ:CERU) recently presented the results on the Phase Ib trial of CRLX101 with weekly paclitaxel for the treatment of platinum-resistant ovarian cancer. The nine-patient trial showed a 56% overall response rate (ORR). The company also reported data from the Phase I/IIa dose escalation trial of CRLX301 (docetaxel nanoparticle conjugate) for solid tumors. The primary purpose of the study was to determine the maximum tolerated dose, but six of the 13 patients evaluable for efficacy were stabilized during the study.
CRLX101 + paclitaxel: Higher ORR than with Avastin
The Phase Ib trial of CRLX101 and weekly paclitaxel showed a higher ORR (56%) than the recently reported results of CRLX101 and Avastin (17%). Additionally, the ORR was higher than a previous study of paclitaxel as a monotherapy (21%), suggesting an additive benefit from CRLX101. One interesting finding, however, was that the clinical benefit rate (CBR) in the current trial was lower (67%) compared to the Avastin trial (94%).
To read the entire report Please click on the pdf File Below